SunHo (China) BioPharmaceutical Co., Ltd.
A biopharmaceutical company focused on discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
SunHo (China) BioPharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems. The company develops various types of immunotherapies, including antibody-cytokines for the treatment of cancer and autoimmune diseases. Its proprietary technology platforms include the AIC™ platform for antibody-cytokine fusion proteins, the AEA™ platform for enhanced antibody-dependent cellular cytotoxicity, and the AIM™ platform for innate immunity-stimulating multispecific antibodies. The company has a global innovative and differentiated pipeline of 9 programs, with 6 in clinical development, and employs 117 people, with 62.2% of R&D personnel holding master's degrees or above. It has established GMP-compliant production facilities with four production lines for drug substance, a total bioreactor capacity of 1600 liters, and a 5000-liter bioreactor line installed and qualified. Its formulation facilities include a liquid injection filling line and a lyophilized powder line.
History
SunHo (China) BioPharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems. The company develops various types of immunotherapies, including antibody-cytokines for the treatment of cancer and autoimmune diseases. Its proprietary technology platforms include the AIC™ platform for antibody-cytokine fusion proteins, the AEA™ platform for enhanced antibody-dependent cellular cytotoxicity, and the AIM™ platform for innate immunity-stimulating multispecific antibodies. The company has a global innovative and differentiated pipeline of 9 programs, with 6 in clinical development, and employs 117 people, with 62.2% of R&D personnel holding master's degrees or above. It has established GMP-compliant production facilities with four production lines for drug substance, a total bioreactor capacity of 1600 liters, and a 5000-liter bioreactor line installed and qualified. Its formulation facilities include a liquid injection filling line and a lyophilized powder line.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sunho-china-biopharmaceutical-co-ltd-china · Editorial policy · How profiles are compiled